• Explore /
  • Poster
  • / Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer.

Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer.

Abstract Poster

Authors

ARTURO LOAIZA-BONILLA

Arturo Loaiza-Bonilla

University of Pennsylvania, Philadelphia, PA

Arturo Loaiza-Bonilla , Mark H. O'Hara , Maryann Redlinger , Nevena Damjanov , Ursina R. Teitelbaum , Irina Vasilevskaya , Mark Alan Rosen , Daniel F Heitjan , Ravi K. Amaravadi , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01206530

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3614)

DOI

10.1200/jco.2015.33.15_suppl.3614

Abstract #

3614

Poster Bd #

107

Abstract Disclosures

Similar Posters

First Author: Angela Damato

First Author: Mark H. O'Hara

First Author: Yutaka Ogata

First Author: Shen Zhao